PAR19 CRITERIA-BASED INTERPRETATION OF SF-36 IMPROVEMENTS FROM ADALIMUMAB PLUS METHOTREXATE (MTX) COMBINATION THERAPY VS. MTX ALONE IN EARLY RHEUMATOID ARTHRITIS (RA)
Nov 1, 2005, 00:00
10.1016/S1098-3015(10)67228-2
https://www.valueinhealthjournal.com/article/S1098-3015(10)67228-2/fulltext
Title :
PAR19 CRITERIA-BASED INTERPRETATION OF SF-36 IMPROVEMENTS FROM ADALIMUMAB PLUS METHOTREXATE (MTX) COMBINATION THERAPY VS. MTX ALONE IN EARLY RHEUMATOID ARTHRITIS (RA)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)67228-2&doi=10.1016/S1098-3015(10)67228-2
First page :
Section Title :
Open access? :
No
Section Order :
452